PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples is a phase 2, interventional study registered as NCT04683315 by Medical College of Wisconsin, with a registry enrolment figure of 84 participants, started 2021-04-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: mFOLFIRINOX Treatment Regimen; Gemcitabine/Nab-paclitaxel Treatment Regimen. Conditions listed: Pancreatic Cancer. Primary outcome: Subjects who receive PurIST classification-directed therapy.. Pancreatic eligibility wording from the registry: "Have suspicion of pancreas adenocarcinoma and plan for endoscopic biopsy". Sites: United States. No results are recorded here; the registry entry is the source.